Abstract
Objective: Objective of the present analytical research work was to develop and validate Reverse Phase High Performance Liquid Chromatographic method (RP-HPLC Method) for the Etoricoxib in bulk and tablets dosage form. Methods: A RP-HPLC method has been developed and validated for estimation of ETOR in pharmaceutical oral dosage form. Method A (RP-HPLC Method): The RP-HPLC Method for Etoricoxib was developed using Shimadzu HPLC, LC-10, temperature maintained 25 0 C, phenorex Gemini C18 (250 mm 4.60 mm 5?m), as stationary particle, isocratic mode. Water: ACN: OPA: TEA (40:60:0.1:0.1, v/vv/v). Mobile phase was maintained at a flow rate of 1.0 ml/min and detection was carried out at 245 nm. Results: Etoricoxib was found to be linear in the concentration range of 8 - 12 ?g/ml for RP-HPLC method. Retention time was found to be 2.7 min for Etoricoxib. The amount of Etoricoxib in marketed formulation was found to be 99.14 %. Interpretation and Conclusion: Results of assay and validation study were found to be satisfactory. So, the method can be successfully applied for the routine analysis of Etoricoxib.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.